One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Defining the Role of Large Language Models in Urologic Care and Research
Raghav Gupta, Adriana M. Pedraza, Michael A. Gorin, Ashutosh K. Tewari
doi : 10.1016/j.euo.2023.07.017
Volume 7, Issue 1, February 2024, Pages 1-13
Does Research from Clinical Trials in Metastatic Hormone-sensitive Prostate Cancer Treatment Translate into Access to Treatments for Patients in the “Real World�? A Systematic Review
Joanna Dodkins a,b,*, Julie Nossiter a,b , Adrian Cook a , Heather Payne a,c , Noel Clarke a,d , Jan van der Meulen a,b , Ajay Aggarwal
doi : 10.1016/j.euo.2023.05.002
Volume 7, Issue 1, February 2024, Pages 14-24
Efficacy and Effectiveness: Bridging the Gap Between Clinical Trials and Real-world Practice
David-Dan Nguyen a , Raj Satkunasivam b,c,d , Christopher J.D. Wallis
doi : 10.1016/j.euo.2023.06.010
Volume 7, Issue 1, February 2024, Pages 25-26
The Impact of Positron Emission Tomography Imaging and Tumor Molecular Profiling on Risk Stratification, Treatment Choice, and Oncological Outcomes of Patients with Primary or Relapsed Prostate Cancer: An International Collaborative Review of the Existing Literature
Akshay Sood a,b,*, Amar U. Kishan c , Christopher P. Evans d , Felix Y. Feng e , Todd M. Morgan f , Declan G. Murphy g , Anwar R. Padhani h , Peter Pinto i , Henk G. Van der Poel j , Derya Tilki k,l,m , Alberto Briganti n , Firas Abdollah
doi : 10.1016/j.euo.2023.06.002
Volume 7, Issue 1, February 2024, Pages 27-43
Circulating tumor DNA as a Predictive and Prognostic Biomarker in the Perioperative Treatment of Muscle-invasive Bladder Cancer: A Systematic Review
Emanuele Crupi a,b,*,y, Tiago Costa de Padua a,y, Laura Marandino a , Daniele Raggi a , Lars Dyrskj?t c , Philippe E. Spiess d , Guru P. Sonpavde e , Ashish M. Kamat f , Andrea Necchi
doi : 10.1016/j.euo.2023.05.012
Volume 7, Issue 1, February 2024, Pages 44-52
Peritoneal Flap for Lymphocele Prophylaxis Following Robotic-assisted Radical Prostatectomy with Lymph Node Dissection: The Randomised Controlled Phase 3 PELYCAN Trial
Manuel Neuberger a,y,*, Karl-Friedrich Kowalewski a,y, Valentin Simon a , Jost von Hardenberg a , Fabian Siegel b , Frederik Wessels a , Thomas S. Worst a , Maurice Stephan Michel a , Niklas Westhoff a , Maximilian C. Kriegmair a , Patrick Honeck a , Philipp Nuhn
doi : 10.1016/j.euo.2023.07.009
Volume 7, Issue 1, February 2024, Pages 53-62
First-in-human Evaluation of a Prostate-specific Membrane Antigen–targeted Near-infrared Fluorescent Small Molecule for Fluorescence-based Identification of Prostate Cancer in Patients with High-risk Prostate Cancer Undergoing Robotic-assisted Prostatectomy
Hao G. Nguyen a,y, Nynke S. van den Berg b,y, Alexander L. Antaris b,y, Lingru Xue a , Scott Greenberg a , J. Walker Rosenthal b , Anna Muchnik b , Alwin Klaassen b , Jeffry P. Simko c , Sanjeev Dutta b , Jonathan M. Sorger b , Pamela Munster d , Peter R. Carroll
doi : 10.1016/j.euo.2023.07.004
Volume 7, Issue 1, February 2024, Pages 63-72
Prospective Validation Study of a Novel Integrated Pathway Based on Clinical Features, Magnetic Resonance Imaging Biomarkers, and MicroRNAs for Early Detection of Prostate Cancer
Martina Pecoraro a,y, Giuseppina Catanzaro b,y, Federica Conte c , Zein Mersini Besharat b , Emanuele Messina a , Ludovica Laschena a , Sofia Trocchianesi d , Elena Splendiani d , Alessandro Sciarra e , Carlo Catalano a , Paola Paci f , Elisabetta Ferretti b,Ã , Valeria Panebianco
doi : 10.1016/j.euo.2023.05.008
Volume 7, Issue 1, February 2024, Pages 73-82
Long-term Outcomes of Chemoradiation for Muscle-invasive Bladder Cancer in Noncystectomy Candidates. Final Results of NRG Oncology RTOG 0524—A Phase 1/2 Trial of Paclitaxel + Trastuzumab with Daily Radiation or Paclitaxel Alone with Daily Irradiation
Douglas M. Dahl a,*, Theodore G. Karrison b,c , M. Dror Michaelson a , Huong T. Pham d , Chin-Lee Wu a , Gregory P. Swanson e , William U. Shipley a , Jacqueline Vuky f , R. Jeffrey Lee g , Anthony L. Zietman a , Luis Souhami h , Brian K. Chang i , Richard L. Deming j , John A. Ellerton k , Howard M. Sandler l , Joseph P. Rodgers b , Felix Y. Feng m,y, Jason A. Efstathiou
doi : 10.1016/j.euo.2023.05.013
Volume 7, Issue 1, February 2024, Pages 83-90
Randomized Controlled Feasibility Trial of Robot-assisted Versus Conventional Open Partial Nephrectomy: The ROBOCOP II Study
Karl-Friedrich Kowalewski a,*,y, Manuel Neuberger a,y, Marie Angela Sidoti Abate a , Marietta Kirchner b , Caelan Max Haney c , Fabian Siegel a , Niklas Westhoff a , Maurice-Stephan Michel a , Patrick Honeck a , Philipp Nuhn a , Maximilian Christian Kriegmair
doi : 10.1016/j.euo.2023.05.011
Volume 7, Issue 1, February 2024, Pages 91-97
Robotic Versus Open Partial Nephrectomy: From the “Shadows� of Randomized Controlled Trials to the “Reality� of Value-based Care for Patients with Localized Renal Masses
Riccardo Campi a,b,c,*, Alessio Pecoraro a , Sergio Serni a,b , Andrea Minervini
doi : 10.1016/j.euo.2023.06.003
Volume 7, Issue 1, February 2024, Pages 98-101
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?
Matteo Santoni a,y, Sebastiano Buti b,y, Zin W. Myint c , Marco Maruzzo d , Roberto Iacovelli e , Martin Pichler f , Jindrich Kopecky g , Jakub Kucharz h , Mimma Rizzo i , Luca Galli j , Thomas Bu¨ttner k , Ugo De Giorgi l , Ravindran Kanesvaran m , Ondr?ej Fiala n , Enrique Grande o , Paolo Andrea Zucali p,q , Ray Manneh Kopp r , Giuseppe Fornarini s , Maria T. Bourlon t , Sarah Scagliarini u , Javier Molina-Cerrillo v,*, Gaetano Aurilio w , Marc R. Matrana x , Renate Pichler y , Carlo Cattrini z , Tomas Bu¨chler aa , Francesco Massari bb , Emmanuel Seront cc , Fabio Calabro` dd , Alvaro Pinto ee , Rossana Berardi ff , Anca Zgura gg , Giulia Mammone hh , Jawaher Ansari ii , Francesco Atzori jj , Rita Chiari kk , Aristotelis Bamias ll , Orazio Caffo mm , Giuseppe Procopio nn,oo , Kaisa Sunela pp , Maria Bassanelli qq , Cinzia Ortega rr , Francesco Grillone ss , Johannes Landmesser tt , Michele Milella uu , Carlo Messina vv , Zso´fia Ku¨ronya ww , Alessandra Mosca xx , Dipen Bhuva yy , Daniele Santini zz , Nuno Vau aaa , Franco Morelli bbb , Lorena Incorvaia ccc , Sara Elena Rebuzzi ddd,eee , Giandomenico Roviello fff , Andrey Soares ggg,hhh , Renato Bisonni iii , Davide Bimbatti d , Ignacio Ortego Zabalza o , Alessandro Rizzo jjj , Veronica Mollica bb , Giulia Sorgentoni a , Fernando Sabino M. Monteiro ggg,kkk , Nicola Battelli a , Sergio Bracarda lll,à , Camillo Porta
doi : 10.1016/j.euo.2023.07.003
Volume 7, Issue 1, February 2024, Pages 102-111
Prognostic Significance of Grade Discrepancy Between Primary Tumor and Venous Thrombus in Nonmetastatic Clear-cell Renal Cell Carcinoma: Analysis of the REMEMBER Registry and Implications for Adjuvant Therapy
Zhenjie Wu a,b,y,*, Hui Chen c,y, Qi Chen d,y, Silun Ge e,y, Nengwang Yu f,y, Riccardo Campi b,g,h , Juan Go´mez Rivas i , Riccardo Autorino j , Morgan Roupreˆt k , Sarah P. Psutka l , Reza Mehrazin m , Francesco Porpiglia n , Karim Bensalah o , Peter C. Black p , Maria C. Mir q , Andrea Minervini r , Hooman Djaladat s , Vitaly Margulis t , Riccardo Bertolo b,u , Anna Calio` b,v , Umberto Carbonara b,w , Daniele Amparore b,n , Leonardo D. Borregales b,x , Chiara Ciccarese b,y , Pietro Diana b,z , Selcuk Erdem
doi : 10.1016/j.euo.2023.06.006
Volume 7, Issue 1, February 2024, Pages 112-121
Retroperitoneal Lymph Node Dissection in Clinical Stage IIA/B Metastatic Seminoma: Results of the COlogne Trial of Retroperitoneal Lymphadenectomy In Metastatic Seminoma (COTRIMS)
Axel Heidenreich a,b,*, Pia Paffenholz a , Florian Hartmann a , Felix Seelemeyer a , David Pfister
doi : 10.1016/j.euo.2023.06.004
Volume 7, Issue 1, February 2024, Pages 122-127
Proposal for a Novel Histological Scoring System as a Potential Grading Approach for Muscle-invasive Urothelial Bladder Cancer Correlating with Disease Aggressiveness and Patient Outcomes
Markus Eckstein a,b,c , Christian Matek a,b,c , Paul Wagner a,b,c , Ramona Erber a,b,c , Maike Bu¨ttner-Herold a,b,c,d , Peter J. Wild e , Helge Taubert f , Sven Wach f , Danijel Sikic f , Bernd Wullich f , Carol I. Geppert a,b,c , Eva M. Compe´rat g , Antonio Lopez-Beltran h , Rodolfo Montironi i , Liang Cheng j,k , Theodorus van der Kwast l , Maurizio Colecchia m , Bas W.G. van Rhijn n,o , Mahul B. Amin p,q , George J. Netto r , Jan Lehmann s,t , Michael Sto¨ckle u , Kerstin Junker v , Arndt Hartmann a,b,c , Simone Bertz
doi : 10.1016/j.euo.2023.07.011
Volume 7, Issue 1, February 2024, Pages 128-138
Downstaging and Survival Associated with Neoadjuvant Immunotherapy Before Radical Cystectomy for Muscle-invasive Bladder Cancer
Jacob Grassauer a,y, Jackson Schmidt a,*,y, Andrew Cowan a , Scott M. Gilbert b , Nicholas H. Chakiryan
doi : 10.1016/j.euo.2023.06.005
Volume 7, Issue 1, February 2024, Pages 139-146
Stereotactic Magnetic Resonance–guided Adaptive Radiation Therapy for Localized Kidney Cancer: Early Outcomes from a Prospective Phase 1 Trial and Supplemental Cohort
Kendrick Yim a,y, Shu-Hui Hsu b,y, Jose´ Ignacio Nolazco a , Daniel Cagney b , Raymond H. Mak b , Vincent D’Andrea a , Lisa Singer b , Christopher Williams b , Elizabeth Huynh b , Zhaohui Han b , Neil Martin b , Paul Nguyen b , Adam S. Kibel a , Toni K. Choueiri c , Steven L. Chang a , Jonathan E. Leeman
doi : 10.1016/j.euo.2023.07.002
Volume 7, Issue 1, February 2024, Pages 147-150
Changes in Prostate-specific Antigen Screening after the 2018 United States Preventive Services Task Force Recommendations and Through the COVID-19 Pandemic
Zhiyu Qian a,b , Xi Chen b , Alexander P. Cole a,b , Firas Abdollah c,d , Toni K. Choueiri e , Adam S. Kibel a,b , Stuart R. Lipsitz b , Hari S. Iyer f , Quoc-Dien Trinh
doi : 10.1016/j.euo.2023.07.007
Volume 7, Issue 1, February 2024, Pages 151-154
Would Uro_Chat, a Newly Developed Generative Artificial Intelligence Large Language Model, Have Successfully Passed the In-Service Assessment Questions of the European Board of Urology in 2022?
Matthias May a,* Katharina K?rner-Riffard b Martin Marszalek c Klaus Eredics
doi : 10.1016/j.euo.2023.08.013
Volume 7, Issue 1, February 2024, Pages 155-156
Large Language Models in Uro-oncology
Dyke Ferber a,b , Jakob Nikolas Kather
doi : 10.1016/j.euo.2023.09.019
Volume 7, Issue 1, February 2024, Pages 157-159
Development of a Personalized Chat Model Based on the European Association of Urology Oncology Guidelines: Harnessing the Power of Generative Artificial Intelligence in Clinical Practice
Zine-Eddine Khene a Pierre Bigot b Romain Mathieu a Morgan Rouprêt
doi : 10.1016/j.euo.2023.06.009
Volume 7, Issue 1, February 2024, Pages 160-162
Re: Wei Shen Tan, Ian M. McElree, Facundo Davaro, et al. Sequential Intravesical Gemcitabine and Docetaxel Is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non–muscle-invasive Bladder Cancer. Eur Urol Oncol. 2023;6:531–534
Wen-Wei Sung
doi : 10.1016/j.euo.2023.08.007
Volume 7, Issue 1, February 2024, Page 163
Reply to Wen-Wei Sung’s Letter to the Editor re: Wei Shen Tan, Ian M. McElree, Facundo Davaro, et al. Sequential Intravesical Gemcitabine and Docetaxel Is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non–muscle-invasive Bladder Cancer. Eur Urol Oncol. 2023;6:531–534
Wei Shen Tan a Michael O’Donnell b Roger Li c Ashish M. Kamat a,* Vignesh T. Packiam
doi : 10.1016/j.euo.2023.10.009
Volume 7, Issue 1, February 2024, Pages 164-165
Reply to Ugo Giovanni Falagario, Alberto Martini, Francesco Pellegrino, et al.’s Letter to the Editor re: Derya Tilki, Ming-Hui Chen, Jing Wu, et al. Prostate-specific Antigen Level at the Time of Salvage Therapy After Radical Prostatectomy for Prostate Cancer and the Risk of Death. J Clin Oncol 2023;41:2428–35
Derya Tilki a,b,c,* Ming-Hui Chen d Anthony V. D’Amico
doi : 10.1016/j.euo.2023.05.009
Volume 7, Issue 1, February 2024, Page 166
Re: Derya Tilki, Ming-Hui Chen, Jing Wu, et al. Prostate-specific Antigen Level at the Time of Salvage Therapy After Radical Prostatectomy for Prostate Cancer and the Risk of Death. J Clin Oncol 2023;41:2428–35
Ugo Giovanni Falagario a,b,* Alberto Martini c Francesco Pellegrino a,d,e Giuseppe Carrieri b Mani Manon f Anna Lantz a,c,g Peter Wiklund
doi : 10.1016/j.euo.2023.05.006
Volume 7, Issue 1, February 2024, Pages 167-168
Re: Francesco Giganti, Louise Dickinson, Clement Orczyk, et al. Prostate Imaging After Focal Ablation (PI-FAB): A Proposal for a Scoring System for Multiparametric MRI of the Prostate After Focal Therapy. Eur Urol Oncol. 2023;6:629–634
Jorge Abreu-Gomez Masoom Haider Sangeet Ghai
doi : 10.1016/j.euo.2023.07.015
Volume 7, Issue 1, February 2024, Pages 169-170
Re: Freddie C. Hamdy, Jennie L. Donovan, J. Athene Lane, et al. Fifteen-year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med 2023;388:1547–58
Fabio Campodonico
doi : 10.1016/j.euo.2023.06.012
Volume 7, Issue 1, February 2024, Page 171
Re: Bradley McGregor, Daniel M. Geynisman, Mauricio Burotto, et al. A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma. Eur Urol Oncol. 2023;6:339–348
Juskaran Chadha Jad Chahoud
doi : 10.1016/j.euo.2023.06.001
Volume 7, Issue 1, February 2024, Page 172
